Verily
https://verily.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Verily
Alzheimer’s Evidence Accelerator Modeled On FDA COVID Project Floated By USAgainstAlzheimer’s
Patient organization exploring development of a multi-stakeholder forum on real world evidence that, among other things, could address research questions posed by the Centers for Medicare and Medicaid Services in its national coverage determination for Alzheimer’s drugs.
US FDA Leadership Team: Woodcock’s Next Chapter
The announcement of US FDA Deputy Commissioner’s new focus going forward at the agency may not mean what you think it does. The focus shouldn’t be on what Janet Woodcock is not doing – but on the fact that she is staying on at the agency at all.
Exec Chat: As Reimbursement Questions Get Answers, iRhythm Looks To The Future
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.
Moving Beyond Aduhelm: Cell/Gene Therapy May Be ‘Poster Child’ For What Comes Next
Former FDA principal deputy commissioner Amy Abernethy says cell and gene therapy is an area primed for improved ‘parallel conversation’ between FDA and CMS on data requirements.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Glucose Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Alphabet Inc.
- Verily Life Sciences LLC